Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.44 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,633
Open 125.44
Bid (Size) 125.02 (1)
Ask (Size) 125.80 (1)
Prev. Close 125.44
Today's Range 125.44 - 125.44
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill

Performance

YTD
+10.77%
+10.77%
1 Month
-1.62%
-1.62%
3 Month
+0.30%
+0.30%
6 Month
+5.87%
+5.87%
1 Year
+18.82%
+18.82%

More News

Read More
3 Biotech Stocks to Buy in Case of Another Pandemic
Via InvestorPlace
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
From Merck & Co., Inc.
Via Business Wire
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
Via The Motley Fool
Merck's Acquisition of EyeBio Finalized
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Via Benzinga
Merck Completes Acquisition of EyeBio
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity
Via Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
Via InvestorPlace
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Via Talk Markets
Topics Stocks
Exposures US Equities
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Via InvestorPlace
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
Via InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.